左主支疾病:醫(yī)證據(jù)基礎(chǔ)和現(xiàn)實(shí)世界英文課件_第1頁(yè)
左主支疾?。横t(yī)證據(jù)基礎(chǔ)和現(xiàn)實(shí)世界英文課件_第2頁(yè)
左主支疾?。横t(yī)證據(jù)基礎(chǔ)和現(xiàn)實(shí)世界英文課件_第3頁(yè)
左主支疾病:醫(yī)證據(jù)基礎(chǔ)和現(xiàn)實(shí)世界英文課件_第4頁(yè)
左主支疾?。横t(yī)證據(jù)基礎(chǔ)和現(xiàn)實(shí)世界英文課件_第5頁(yè)
已閱讀5頁(yè),還剩25頁(yè)未讀 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

1、lu shuzheng m.d. fapsic.beijing anzhen hospitalcapital medical universityleft main disease: evidence-base medicine & realistic worldanatomy importance of lmocompromises flow to approximately 75% of the left ventricle;oacute occlusion of ulmca will cause mi ,cardiac shock or acute heart failure,

2、cardiac arrest(50%70%).anatomy features of lmca diseaseomost elastic tissue;ohigher elastic radial force.classification based on location of lesionsostium shaft/body distalclinical results of des for ulmcades for the ulmcapatients, ndistal lesion location(%)cardiac mortality,612 months(%)angiographi

3、c follow up(%)angiographic restenosis (%)tlr or tvr(%)park et al.10271084.37 *2 chieffo et al.85813.5nr19 18.8 valgimgli et al.956511nrnr6.3 lee et al.5060442nr13 price et al.509429844 38 migliorini et al.10187119616 *14 erglis et al.538121006 *2 *follow-up angiography at 6 moths. fellow-up angiogra

4、phy at 4 to 8 months. fellow-up angiography at 3 and 9 months. target lessin revascularization. target vessel revascularization (tvr). date from baim et al.des drug eluting stent; nr not reported. (3.7-7.7)recent meta-analysis of 1,278 patients undergoing uplm des from 15 registriesdate from biondi-

5、zoccai et aldes for the ulmca(3.4-7.7)recent meta-analysis of 1,278 patients undergoing uplm des from 15 registriesdate from biondi-zoccai et aldes for the ulmca(3.7-9.2)pci vs. cabg bologna registrypci vs. cabg milan experiencepci vs. cabg cedars sinai registryle mans study designnumber of patients

6、 screened with ulmca disease:347patients eligible for study:122patients noneligible for study included in le mans registry:225randomized patients:105nonrandomized patients:17pci102cabg123pci52cabg53pci9cabg8all patients treated according to randomization (no crossover)first rct study of ulmcale mans

7、 study baselinevariablesage (yrs)male (%)ccs classlvef (%)distal lm disease (%)no. of diseased vesselsdes/arterial graft to lad (%) complete revascularization (%)hospitalization (days)pci(n=52)60.610.5603.11.021561.730.9335796.8 3.7cabg(n=53)61.38.4732.81.017602.08 0.83818912.04 9.6p value0.690.130.

8、170.580.630.33-0.170.0007le mans study lvef at baseline and after 12 monthsp=0.22p=0.04p=0.01p=0.85le mans study ccs function class at baseline and follow-upp=0.22p=0.01p=0.10p=0.01p=0.11le mans study treadmill stress tests at baseline and follow-upp=0.03p=0.31p=0.97p=0.53le mans studypcicabgsurviva

9、l after pci and cabgmacce-free survival after pci and cabgpcicabgmore rct trial neededulmca in realistic worldleft main strategiesostium lesionsshaft lesionsbifurcation lesionswhat do you think about this patientomale, 73y;oexertional chest pain 3m, aggravated 10d;odiag: cad uap braunwald b;oother r

10、f: ht, smoking;oecho: ef 68%, lvedd 50mm;oto cath lab.4 bifurcation lesions o which one is the first;o technique of each lesion; o v/t/kissing stent for lm;o how to do the final kissing.crossovert stentt stentcrushgc: 7f jl4; gw: stablizer supersoft, runthrough, rinato, atw; bc: sprinter 2.5*15mm, s

11、printer 1.5*15mm;sc: ses 3.0*24mm, ses 2.5*33mmsc: ses 2.5*18mm, ses 3.5*18mmgw: pilot50; bc: sequent 3.0*10mm sc: ses 4.0*15mmfinal resultcabg vs. des our experienceslesions distributionfrom 2004 to 2006, 393 pts with lm lesions, fu 4y, registry study255 pts in cabg group & 138 pts in des groupdifferent techniques of bifurcation lesionscabg vs. des our experiencesp0.05prognosis

溫馨提示

  • 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

評(píng)論

0/150

提交評(píng)論